NasdaqCM - Delayed Quote USD

GlycoMimetics, Inc. (GLYC)

0.2470
-0.0028
(-1.12%)
At close: May 16 at 4:00:02 PM EDT
0.2465
-0.00
(-0.20%)
After hours: May 16 at 7:49:58 PM EDT
Loading Chart for GLYC
  • Previous Close 0.2498
  • Open 0.2531
  • Bid --
  • Ask --
  • Day's Range 0.2470 - 0.2670
  • 52 Week Range 0.1400 - 0.6300
  • Volume 170,582
  • Avg. Volume 1,242,562
  • Market Cap (intraday) 15.935M
  • Beta (5Y Monthly) --
  • PE Ratio (TTM) --
  • EPS (TTM) -0.5900
  • Earnings Date Aug 6, 2025 - Aug 11, 2025
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

GlycoMimetics, Inc. engages in the discovery and development of therapies for cancers and inflammatory diseases in the United States. The company was founded in 2003 and is based in Monrovia, Maryland.

www.glycomimetics.com

4

Full Time Employees

December 31

Fiscal Year Ends

Recent News: GLYC

View More

Performance Overview: GLYC

Trailing total returns as of 5/16/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

GLYC
1.20%
S&P 500 (^GSPC)
1.30%

1-Year Return

GLYC
11.79%
S&P 500 (^GSPC)
12.48%

3-Year Return

GLYC
58.83%
S&P 500 (^GSPC)
48.66%

5-Year Return

GLYC
92.06%
S&P 500 (^GSPC)
108.07%

Compare To: GLYC

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: GLYC

View More

Valuation Measures

Annual
As of 5/16/2025
  • Market Cap

    15.93M

  • Enterprise Value

    5.28M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    --

  • Price/Book (mrq)

    3.00

  • Enterprise Value/Revenue

    --

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -73.99%

  • Return on Equity (ttm)

    -182.66%

  • Revenue (ttm)

    --

  • Net Income Avi to Common (ttm)

    -29.49M

  • Diluted EPS (ttm)

    -0.5900

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    5.61M

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    -10.52M

Research Analysis: GLYC

View More

Company Insights: GLYC

Research Reports: GLYC

View More

People Also Watch